Clinical Stage Evaluation at Diagnosis of Prostate Cancer at Urology-Andrology Clinic Cnhu-Hkm Cotonou


Aims: To evaluate the clinical stage at diagnosis of prostate cancer. Materials and Methods: This study was retrospective and descriptive from January 2008 to June 2013. Patients who were diagnosed with prostate cancer wereinvolved and confirmed by clinical examination anatomopathological screening. They also realized a total serum PSA, a bladder-prostatic and abdominal ultrasound. Results: Average age was seventy years, ranging from fifty years to seventy years. The general status of our patients was satisfactory in 78% of cases. Main symptoms were dysuria and frequencyin 96% and 86%, respectively. Family past history of prostate cancer were found in 24% of cases. Twenty-three patients (43%) had a total serum PSA ≥ 100 ng/ml. Adenocarcinoma was the main histological type. Grades 1 and 4 were the most frequent. Thirty-three patients (66%) had a Gleasonscore betwen [2]-[6]. Forty-four patients (88%) had locally advanced and metastatic desease. The D’Amico score was identified in six patients but 3 and 2 patients were low risk and intermediate riskrespectively. Finally, 1 patient was high risk. Conclusion: Prostate cancer remains elderly man cancer. It was discovered in locally advanced and metastatic desease in this series. This diagnosis was late in the majority of cases.

Share and Cite:

Pascal, H. , Dejinnin Georges, A. , Kolawalé Yde, S. , Dossavi, K. , Magloire, Y. and Alexandre, V. (2015) Clinical Stage Evaluation at Diagnosis of Prostate Cancer at Urology-Andrology Clinic Cnhu-Hkm Cotonou. Open Journal of Urology, 5, 19-23. doi: 10.4236/oju.2015.53004.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Amegbor, K., Yao Seddoh, T., Tengue, K., Napo-Koura, G., Songne-Gnamkoulamba, B. and James, K. (2009) Epidemiology and Histopronostic of Prostatic Cancer in Togo: About 202 Cases Diagnosed at the Laboratory of Pathology of the Tokoin Teaching Hospital of Lome. Progres en Urologie, 19, 112-115.
[2] Soulie, M. (2003) Cancer Epidemiology. Progres en Urologie, 13, 1261.
[3] Aus, G., Hugosson, J. and Norlen, L. (1995) Long-Term Survival and Mortality in Prostate Cancer Treated with Non Curative Intent. Journal of Urology, 154, 460-465.
[4] McNeal, J. (1968) Rjegional Morphology and Pathology of the Prostate. American Journal of Pathology, 49, 347-357.
[5] Soulie, M., Barre, C., Beuzeboc, P., Chautard, D., Cornud, F., Eschwege, P., Fontaine, E., Molinie, V., Moreau, J.L., Peneau, M., Ravery, V., Rebillard, X., Richaud, P., Ruffion, A., Salomon, L., Staerman, F. and Villers, A., Comite de Cancerologie de l’Association Française d’Urologie (2004) Prostatic Cancer. Progres en Urologie, 14, 913-955.
[6] Niang, L., Ndoye, M., Ouattara, A., Jalloh, M., Labou, I., Thia, I., Kouka, S.C., Diaw, J.J. and Gueye, S.M. (2013) Management of Prostate Cancer in Senegal: What Is Being Done? Progres en Urologie, 23, 36-41.
[7] Catalona, W., Richie, J., Ahman, F., Hudson, M., Scardino, P., Flanigan, R., Dekernion, J.B., Ratliff, T.L., Kavoussi, L.R. and Dalkin, B.L. (1994) Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen. Journal of Urology, 151, 1283-1290.
[8] Stamey, T., Johnstone, I., McNeal, J., Ay, L.U. and Yemoto, C.M. (2002) Preoperative Serum Prostate Specific Antigen Levels. Journal of Urology, 167, 103-111.
[9] Villers, A., Rébillard, X., Soulié, M., Davin, J., Coloby, P., Moreau, J., Mejean, A., Irani, J., Coulange, C. and Mangin, P., French Association of Urology (2003) Prostate Cancer Screening. Progres en Urologie, 13, 209-214.
[10] Boccon-Gibod, L. Prostate Cancer: Diagnostic and Therapeutic Strategies. AKOS Encyclopedia of Medicine Practice, 5-0692.
[11] Descotes, J., Hubert, J., Rouvière, O. and Artignan, X. (2003) Urology Imaging: Contribution of Imaging in Prostatic Cancer. Progrès en Urologie, 13, 843-884.
[12] Sandhu, D., Mayor, P., Sambrook, P. and George, N. (1992) Outcome and Prognostic Factors in Patients with Advanced Prostate Cancer and Obstructive Uropathy. British Journal of Urology, 70, 412-416.
[13] Paule, B. and Cicco, A. (2001) Biphosphonates in the Treatment of Bone Metastasis of Prostatic Cancer. Progrès en Urologie, 11, 1205-1212.
[14] Prost, J., Gros, N., Bastide, C., Bladou, F., Serment, G. and Rossi, D. (2001) Correlation between Gleason Score of Prostatic Biopsies and the One of the Radical Prostatectomy Specimen. Progrès en Urologie, 11, 45-48.
[15] Rigaud, J., Le Normand, L., Karam, G., Glemain, P., Buzelin, J.M. and Bouchot, O. (2002) Prognostic Factors of Prostate Cancer Treated with First-Line Hormone Therapy. Progrès en Urologie, 12, 232-239.
[16] Salomon, L., Azria, D., Bastide, C., Beuzeboc, P., Cormier, L., Cornud, F., Eiss, D., Eschwege, P., Gaschignard, N., Hennequin, C., Molinie, V., Mongiat Artus, P., Moreau, J.L., Peneau, M., Peyromaure, M., Ravery, V., Rebillard, X., Richaud, P., Rischmann, P., Rozet, F., Staerman, F., Villers, A. and Soulie, M., Oncology Committee of the French Association of Urology (CCAFU) (2010) Recommendations Onco-Urology 2010: Prostate Cancer. Progrès en Urologie, 20, S217-S252.
[17] Walz, J., Marcy, M., Maubon, T., Brunelle, S., Laroche, J., Gravis, G., Salem, N. and Bladou, F. (2011) Real Time Elastography in the Diagnosis of Prostate Cancer: Comparison of Preoperative Imaging and Histology after Radical Prostatectomy. Progrès en Urologie, 21, 925-931.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.